[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Cooper Health System\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":351},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,45,84,116,140,166,198,228,254,279,306,329],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100626031","phase-1-buprenorphine-for-analgesia-in-older-adults-with-acute-fractures-in-the-emergency-department-100626031",false,"NCT07430345","Buprenorphine for Analgesia in Older Adults With Acute Fractures in the Emergency Department","Buprenorphine for Analgesia in Older Adults With Acute Fractures in the Emergency Department: a Randomized Controlled Study","Inclusion Criteria:\n\n* Age 65 years or older\n* Emergency Department patient\n* Diagnosis of suspected or confirmed acute fracture\n* Numerical Rating Scale 4 or greater at time of presentation\n* Must be able to give informed consent or have a surrogate decisionmaker to provide informed consent\n* Subjects who may require a surgical procedure are eligible for enrollment, as given the low dose of buprenorphine, this is not anticipated to affect future anesthesia. If additional pain control is needed for surgical procedure, full agonist opioid can be used without contraindication.\n\nExclusion Criteria:\n\n* Prior history of opioid use disorder\n* Participants taking chronic opioid therapy (defined as opioids taken during the past month)\n* Allergy to study medications\n* Hemodynamic instability requiring immediate resuscitation\n* Inability to consent and absence of surrogate decisionmaker","ALL","65 Years",{"count":19,"type":20},48,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The goal of this clinical trial is to learn if buprenorphine can treat pain in older adults who have broken bones. The main questions it aims to answer are:\n\nIs buprenorphine as effective as opioids to treat pain? Are there less side effects with buprenorphine? Researchers will compare buprenorphine and hydromorphone to see if there are differences in pain control and side effects.\n\nParticipants will be given one of the two study drugs after breaking a bone and asked about their pain scores and side effects for the next 48 hours.",[27],"Fracture",[29,30,31],"buprenorphine","geriatric","analgesia","RECRUITING","2026-06-25",{"date":35,"type":36},"2026-06-29","ACTUAL",{"date":38,"type":36},"2026-05-07",{"date":40,"type":20},"2027-01",{"name":42,"class":43},"The Cooper Health System","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":44},"100568990","incentive-spirometry-to-improve-outcomes-in-lung-cancer-patients-undergoing-concurrent-chemotherapy-and-radiation-therapy-100568990","NCT06688422","Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy","Incentive Spirometry for Respiratory Enhancement Pilot Clinical Trial in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy","INSPIRE-CRT","Inclusion Criteria:\n\n* Confirmed diagnosis of advanced non-small-cell lung cancer\n* Performance status (ECOG 0-1)\n* Eligible for concurrent chemotherapy and radiation\n* 18 years or older\n\nExclusion Criteria:\n\n* Previous lung or thoracic surgery\n* Enrollment in another pulmonary intervention trial\n* Home oxygen usage prior to enrolment\n* Radiological evidence of pleural effusion, pneumothorax, bullous emphysema, - or pneumonitis on staging imaging\n* Presence of active respiratory tract infection\n* Uncontrolled nausea and vomiting\n* Prior exposure to drugs such as amiodarone, bleomycin, or immunotherapy\n* Inability or unwillingness of individual to give written informed consent","18 Years",{"count":55,"type":20},100,[57],"NA","The goal of this clinical trial is to learn if using an incentive spirometer can reduce lung problems in people with advanced lung cancer who are receiving chemotherapy and radiation therapy. The main questions the study aims to answer are:\n\nDoes using an incentive spirometer lower the chances of developing lung inflammation (pneumonitis)? Does it improve overall survival and quality of life?\n\nParticipants will:\n\nUse an incentive spirometer, a device that helps with deep breathing, 10 times every hour while awake.\n\nContinue using the spirometer daily during treatment and for up to three months after treatment.\n\nComplete quality of life assessments at the start of the study and at 3, 6, and 12 months.\n\nResearchers will compare the results to see if the incentive spirometer helps reduce lung problems and improves participants\\' well-being during and after their cancer treatment.",[60,61,62,63,64],"Lung Cancer","Pneumonitis","Radiation-Induced Lung Injury","Immunotherapy-Induced Pneumonitis","Non-Small-Cell Lung Cancer (NSCLC)",[66,67,68,69,70,71,72,73,74,75],"Incentive Spirometry","Chemotherapy","Radiation Therapy","Quality of Life (QoL)","Respiratory Complications","Advanced Lung Cancer","Concurrent Chemoradiotherapy","Pulmonary Toxicity","Immunotherapy Maintenance","Lung Function","2026-04-13",{"date":78,"type":36},"2026-04-15",{"date":80,"type":36},"2024-12-01",{"date":82,"type":20},"2026-12",{"name":42,"class":43},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":21,"phases":95,"briefSummary":96,"conditions":97,"keywords":102,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100626710","phase-2-pre-radiation-chemotherapy-for-newly-diagnosed-high-grade-glioma-100626710","NCT07439172","Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.","A Multi-Centered Evaluation of Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma (HGG): An Approach to Drug Screening That Requires Confirmation","PRC","Inclusion Criteria:\n\n1. Pathologic diagnosis of high-grade glioma\n2. Residual measurable post-operative contrast enhancing tumor\n3. Lack of urgency in requiring immediate radiation or chemotherapy (mass effect, mid-line shift, herniation, etc.)\n4. Ability to provide informed consent\n5. Willingness to comply with all study procedures and availability for the duration of the study\n6. Male or female, aged 18-80.\n7. Karnofsky Performance Status ³70%.\n8. Patients must have the following organ and marrow functions:\n\n   Absolute neutrophil count ≥1,500\u002FµL Platelets ≥100,000\u002FµL Hemoglobin ≥ 9 g\u002FdL Total bilirubin £ 1.5 × institutional upper limit of normal (ULN), (except for patients with known Gilbert's syndrome who must have normal direct bilirubin) AST (SGOT)\u002FALT (SGPT) £ 2.5 × ULN Creatinine £ 1.5 × ULN OR Creatinine clearance ≥ 60 mL\u002Fmin\u002F1.73m2 APTT\u002FPTT ≤ 1.5 × ULN Sodium ≥ the institutional lower limit of normal\n9. Ability to take oral medication and be willing to adhere to the pre-radiation temozolomide regimen\n10. For females of reproductive potential: use of highly effective contraception for at least 1 week prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of pr-radiation temozolomide administration\n11. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner\n12. Patients must have measurable disease as defined by RANO criteria.\n\nExclusion Criteria:\n\n1. Patients receiving any other investigational agents are ineligible.\n2. Patients who had Gliadel wafer or other local therapy placed in the tumor cavity during the tumor resection.\n3. Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to TMZ are ineligible.\n4. Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements, are ineligible.\n5. Pregnant women are excluded from this study because TMZ has potential for teratogenic or abortifacients effects. Breastfeeding should be discontinued if the mother is treated with TMZ.","80 Years",{"count":94,"type":20},70,[24],"Better treatments are needed for high-grade gliomas (HGG), and new ways of treating this disease should be tested. The investigators want to see if giving medicine before radiation works well. After radiation, MRI scans can be harder to understand because radiation changes how the brain looks on the scan. If new medicines are given before radiation, the scans are easier to read.\n\nFirst, the investigators need to find out if giving chemotherapy early works using a drug we already know can treat gliomas. The investigators will start with temozolomide, which is the only chemotherapy approved by the FDA for HGG. If this approach is successful, the investigators can then test new drugs using this screening method.",[98,99,100,101],"High Grade Gliomas","Glioblastoma","Astrocytoma","Oligodendroglioma",[103,99,104,105,100,101,106],"Glioma","High Grade Glioma","Brain Tumor","Temozolomide","NOT_YET_RECRUITING","2026-02-23",{"date":110,"type":36},"2026-02-27",{"date":112,"type":20},"2026-03",{"date":114,"type":20},"2029-09",{"name":42,"class":43},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":21,"phases":125,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":44},"100615708","phase-4-rsv-vaccine-response-in-stem-cell-and-car-t-therapy-recipients-100615708","NCT07296120","RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients","Seroconversion Following RSV Vaccination in Bone Marrow Transplant and CAR-T Patients","Inclusion Criteria:\n\n* Age 18 years or older\n* Diagnosis of hematological malignancy\n* Treatment with HSCT or CAR-T therapy\n* Must be able to give informed consent\n* Must be willing to provide blood samples after HSCT or CAR-T therapy and prior to vaccination\n* Must be willing to provide blood samples at four weeks and six months post-vaccination\n* Must have an insurance plan that covers the cost of recieving the RSV vaccine.\n\nExclusion Criteria:\n\n* History of a severe allergic reaction to any component of the RSV vaccine\n* Use of intravenous immunoglobulin (IVIG) for hypogammaglobulinemia within the past six months",{"count":124,"type":20},30,[126],"PHASE4","This study evaluates whether the RSV vaccine Abrysvo can produce an antibody response in patients with blood cancers who have previously received a hematopoietic stem cell transplant (HSCT) or CAR-T cell therapy. The vaccine targets the prefusion F (preF) protein of RSV, which is an important component of protective immunity against the virus.\n\nThe main goal of the study is to measure the change in antibody levels against the preF protein four weeks after vaccination compared with levels before vaccination. The study will also assess whether participants develop a meaningful immune response, defined as at least a four-fold increase in RSV neutralizing antibody levels four weeks after vaccination.",[129,130,131],"CAR-T Cell Therapy","RSV Immunization","Bone Marrow Transplant - Autologous or Allogeneic","2025-12-18",{"date":134,"type":36},"2025-12-22",{"date":136,"type":20},"2026-01-01",{"date":138,"type":20},"2027-06-30",{"name":42,"class":43},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":21,"phases":149,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":44},"100454883","prospective-study-to-evaluate-high-flow-nasal-cannula-with-monitored-anesthesia-care-during-ebus-bronchoscopy-100454883","NCT05203328","Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy","Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care","Inclusion Criteria:\n\n* age\\>18 years\n* patient undergoing EBUS bronchoscopy with moderate conscious sedation.\n\nExclusion Criteria:\n\n* subjects with previous nasal surgeries\n* subjects with oxygen saturation \\\u003C90% on room air prior to procedure\n* subjects who are pregnant\n* subjects with known facial fractures or recent facial trauma\n* subjects on any anticoagulation that cannot be discontinued prior to the procedure",{"count":148,"type":20},198,[57],"Our objective is to assess whether the use of high flow nasal cannula (Vapotherm, Exeter, NH) with monitored anesthesia care (MAC) during an endobronchial ultrasound (EBUS) bronchoscopy procedure will lead to less procedure interruptions, less hypoxic episodes, shorter duration of hypoxic episodes and shorter procedural durations when compared to regular MAC using a regular nasal canula.",[60],[153,154,155,156,157],"EBUS","bronchoscopy","Vapotherm","high-flow nasal cannula","monitored anesthesia care (MAC)","2025-09-22",{"date":160,"type":36},"2025-09-25",{"date":162,"type":36},"2022-02-01",{"date":164,"type":20},"2026-05",{"name":42,"class":43},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":44},"100603891","phase-3-the-effect-of-bacterial-decolonization-before-skin-cancer-surgery-on-infection-rate-of-lower-extremity-wounds-left-open-to-heal-100603891","NCT07142408","The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal","The Effect of Pre-Operative Bacterial Decolonization on Post-Operative Infection Rate for Lower Extremity Wounds Healing by Second Intention","Inclusion Criteria:\n\n* Age at least 18 years old\n* Scheduled to undergo surgical treatment for skin cancer on the lower extremities and have no other surgeries scheduled in the coming weeks after the procedure\n* Will have a surgical wound that will be left open to heal by secondary intention\n\nExclusion Criteria:\n\n* Age under 18 years old\n* Have a known allergy to chlorhexidine or mupirocin\n* Have a history of Staphylococcus aureus infection\n* Have a history of heart valve or joint replacement surgery requiring pre-operative antibiotics",{"count":174,"type":20},848,[176],"PHASE3","The goal of this clinical trial is to learn if reducing bacterial load on the skin and nostrils with topical antibacterial soap and ointment, respectively, reduces rate of infection in surgical sites on lower leg wounds left open to heal in adults undergoing skin cancer surgery.\n\nThe main question it aims to answer is:\n\nDoes Hibiclens antibacterial skin cleanser and mupirocin antibacterial ointment applied to nostrils prior to surgery lower the number of times participants develop an infection in their open wound on the lower leg?\n\nResearchers will compare the treatment group to the standard of care, which involves no treatment prior to surgery, to see if topical antibiotics applied prior to surgery affect infection rates between the two groups.\n\nParticipants randomized to the treatment group will:\n\nShower with Hibiclens once daily for 5 days prior to the day of surgery and apply mupirocin to the nostrils twice daily for 5 days prior to the day of surgery. They will then send pictures of their surgical site to monitor for signs of infection at 2-week and 4-week post-operation.\n\nParticipants randomized to the control group (standard of care) will:\n\nNOT apply the topical antibacterials prior to the day of surgery. They will then send pictures of their surgical site to monitor for signs of infection at 2-week intervals for 1 month after surgery.",[179],"Surgical Wound Infection",[181,182,183,184,185,186,187,188,189],"Lower Extremity Wound","Skin Cancer Surgery","Infection Rate","Prophylactic Topical Antibiotics","Chlorhexidine","Mupirocin","Wound Healing","Secondary Intention","Infection Prevention","2025-08-22",{"date":192,"type":36},"2025-08-26",{"date":194,"type":36},"2023-03-13",{"date":196,"type":20},"2030-12",{"name":42,"class":43},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":21,"phases":208,"briefSummary":209,"conditions":210,"keywords":214,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":44},"100596176","placing-external-ventricular-drains-using-assistive-augmented-reality-or-image-based-localization-100596176","NCT07042048","Placing External Ventricular Drains Using Assistive Augmented Reality or Image-Based Localization","Placing External Ventricular Drains Using Assistive Augmented Reality or Image-Based Localization: A Randomized Controlled Clinical Trial (PEARL)","PEARL","Inclusion Criteria:\n\n* adult patient at time of screening\n* diagnosis of spontaneous ICH with IVH with severe TBI\n* Meet one or more of the following clinical or radiographic criteria:\n\nTissue swelling on imaging Dysmorphic ventricles on imaging Midline shift \\>2mm on imaging Mass effect on imaging Evans Index \\\u003C0.3 on imaging Glasgow Coma Scale 3-8\n\n* admitted to Cooper University Health\n* requires an EVD\n\nExclusion Criteria:\n\n* Other concomitant intracranial pathology (e.g., tumor, tumor-related edema\u002Fhemorrhage, congenital condition, etc.)\n* Concurrent participation in another research protocol for investigation of an experimental therapy\n* Known or suspected inability to adhere to study protocol or protocol requirements, as per the discretion of the investigator",{"count":207,"type":20},50,[57],"The goal of this clinical trial is to assess if EVD placement using augmented reality is non inferior to image-guidance systems for assistance in adult patients needing an EVD for spontaneous ICH with IVH or severe TBI. The main question it aims to answer is:\n\nCan EVDs be placed successfully with at least equal safety and efficacy using augmented reality devices in comparison to using standard image-guidance techniques?",[211,212,213],"ICH - Intracerebral Hemorrhage","IVH- Intraventricular Hemorrhage","TBI Traumatic Brain Injury",[215,216,217,218,219],"EVD","Augmented Reality","TBI","ICH","Image Guidance","2025-06-25",{"date":222,"type":36},"2025-06-27",{"date":224,"type":20},"2025-07-01",{"date":226,"type":20},"2026-03-31",{"name":42,"class":43},{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":21,"phases":238,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":44},"100555322","phase-1-chronic-subdural-hematoma-treatment-with-intra-arterial-bevacizumab-injection-100555322","NCT06510582","Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection","Chronic Subdural Hematoma Treatment With Avastin® (Bevacizumab) Intra-Arterial Injection: A Non-Randomized, Open-Label Phase 1\u002F2 Clinical Trial","CHAI","Inclusion Criteria:\n\n* Adult patients (≥18 years)\n* Radiographic evidence of chronic subdural hematoma, including\n\n  1. Persistence of subdural blood more than 10 days after index traumatic injury or event\n  2. Presence of mixed density blood\n  3. Presence of subdural membranes\n* Can obtain informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization.\n\nExclusion Criteria:\n\n* Pregnant, breastfeeding, or unwilling to practice contraception during participation in the study.\n* Patients with concomitant intracranial pathology other than subdural hematoma (e.g., intracranial malignancy).\n* Patients with known hypersensitivity to bevacizumab.\n* Patients with radiographic evidence of mass effect.\n* Patients have focal neurological deficits attributed to subdural hematoma.\n* Patient had craniotomy or burr hole operative procedures performed in preceding two weeks prior to onset of subdural hematoma.\n* Secondary causes apart from trauma for the chronic subdural hematoma, such as underlying vascular abnormality or tumor.\n* Emergent surgical evacuation is required for the patient.\n* Non-convexity chronic subdural hematoma, as the middle meningeal artery will not supply this area.\n* Coagulation abnormalities, including platelet count \\\u003C100,000 and\u002For international normalized ratio of \\\u003C1.5 despite attempts for correction.\n* Patients with known contraindications for angiography. Patients with contrast allergy will be premedicated with diphenhydramine and steroids.\n* Patient has known active systemic infection or sepsis.\n* Patient has contradiction to anesthetic agents used for conscious sedation\u002Fmonitored anesthesia care (MAC).\n* Patient has life expectancy of less than six months due to comorbid terminal conditions.\n* Patient has a premorbid modified Rankin score (mRS) of 5 or greater.\n* Concurrent participation in another research protocol for investigation of an experimental therapy.",{"count":237,"type":20},140,[23,24],"The goal of this clinical trial is to test whether infusing bevacizumab into the middle meningeal arteries can be used to treat chronic subdural hematomas (cSDH).\n\nThe main questions it aims to answer are:\n\n* Is bevacizumab infusion safe in cSDH patients?\n* Is bevacizumab infusion effective in treating cSDH?",[241],"Chronic Subdural Hematoma",[243,244,245,246,247],"Chronic subdural hematoma","Chronic intracranial subdural hematoma","Vascular endothelial growth factor","Bevacizumab","Middle meningeal artery embolization",{"date":224,"type":36},{"date":250,"type":36},"2024-06-17",{"date":252,"type":20},"2028-06",{"name":42,"class":43},{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":260,"sex":16,"minAge":261,"maxAge":262,"enrollmentInfo":263,"targetDuration":4,"studyType":21,"phases":265,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":44},"100494520","standardized-yoga--meditation-program-for-stress-reduction-for-adolescents-with-irritable-bowel-syndrome-100494520","NCT05719246","Standardized Yoga & Meditation Program for Stress Reduction for Adolescents With Irritable Bowel Syndrome","Inclusion Criteria:\n\n* Patients of Cooper Pediatric Gastroenterology practice in Camden, NJ or Voorhees, NJ\n* Patients of Cooper Pediatric Gastroenterology practice in Voorhees, NJ\n* Participants 12 to 21 years old with any type of IBS diagnosis\n* Subjects must be able to access the internet to be able to watch the yoga videos on Youtube\n* Patients must complete 4 out of 6 modules to stay in the study\n\nExclusion Criteria:\n\n* Participants under the age of 12\n* Participants over the age of 21",true,"12 Years","21 Years",{"count":264,"type":20},10,[57],"Irritable Bowel Syndrome (IBS) is the most common cause of recurrent abdominal pain in children. IBS is a functional gastrointestinal disorder that is linked to motor and sensory physiology, as well as the central nervous system, that presents as abdominal pain with abnormal defecation patterns. This discomfort leads to emotional stress, decreased quality of life, and anxiety. The study proposes that yoga and mindfulness will decrease anxiety and increase quality of life for patients with IBS. The aim of this study is to measure the impact of a brief, at-home, 6-week twice per week Standardized Yoga \\& Meditation Program for Stress Reduction program on anxiety, IBS symptoms, and quality of life in children ages 12-21 diagnosed with IBS.",[268,269,270],"Irritable Bowel Syndrome","Anxiety","Quality of Life","2024-10-09",{"date":273,"type":36},"2024-10-15",{"date":275,"type":36},"2020-12-30",{"date":277,"type":20},"2026-12-31",{"name":42,"class":43},{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":16,"minAge":286,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":289,"phases":4,"briefSummary":290,"conditions":291,"keywords":294,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":44},"100526375","duration-of-immobilization-after-reverse-total-arthroplasty-for-proximal-humerus-fractures-100526375","NCT06133920","Duration of Immobilization After Reverse Total Arthroplasty for Proximal Humerus Fractures","Immobilization Versus Early Range of Motion in Reverse Total Arthroplasty in Patients With Proximal Humerus Fractures","Inclusion Criteria:\n\n* Patients 60 years or older who have a displaced proximal humerus fracture\n* Meets surgical criteria for a reverse total shoulder arthroplasty\n* Receive surgical intervention within 6 weeks of initial injury\n\nExclusion Criteria:\n\n* Patients \\\u003C60 years in age\n* Patients who cannot undergo surgery due to medical comorbidities\n* Patients who receive surgical intervention after 6 weeks from initial injury\n* Patients who have preoperative nerve damage from their fractures that would limit the ability to move the arm postoperatively","60 Years",{"count":288,"type":20},40,"OBSERVATIONAL","The purpose of this study is to evaluate compare postoperative range of motion in patients who are given a sling for comfort only and allowed to start early active range of motion compared to patients who are placed in a sling for 4 weeks with passive range of motion only. Once enrolled, the patients will be randomized through computer randomization then placed in paper packets into either the immobilization group or the early range of motion group.",[292,293],"Proximal Humeral Fracture","Reverse Total Shoulder Arthroplasty",[295,296,297],"Proximal Humerus Fracture","Range of Motion","Immobilization","2024-08-19",{"date":300,"type":36},"2024-08-20",{"date":302,"type":36},"2021-02-24",{"date":304,"type":20},"2027-02-01",{"name":42,"class":43},{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":260,"sex":314,"minAge":4,"maxAge":4,"enrollmentInfo":315,"targetDuration":317,"studyType":289,"phases":4,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":44},"100266568","maternal-cancer-diagnosis-and-treatment-during-pregnancya-database-for-maternal-fetal-and-neonatal-outcomes-100266568","NCT02749474","Maternal Cancer Diagnosis and Treatment During Pregnancy:a Database for Maternal, Fetal, and Neonatal Outcomes","Maternal Cancer Diagnosis and Treatment During Pregnancy:a Registry for Maternal, Fetal, and Neonatal Outcomes With Longitudinal Follow up of Child Development and Maternal Psychological Well Being","CANCRPREGREG","Inclusion Criteria:\n\n* Any pregnant woman diagnosed with cancer within 6 weeks before her last menstrual period or 6 months after her end of pregnancy either by delivery or miscarriage.\n\nExclusion Criteria:\n\n* Women diagnosed with cancer more than 6 months after the end of a pregnancy.","FEMALE",{"count":316,"type":20},400,"20 Years","The objective of this study is to follow the treatment options offered to pregnant women diagnosed with cancer and study the impact that their treatment or delay of treatment has on their own health and that of their children.",[320],"Pregnancy, Cancer, Cancer in Pregnancy, Gestational Breast Cancer, Pregnancy Related","2024-06-06",{"date":323,"type":36},"2024-06-10",{"date":325,"type":36},"2003-07",{"date":327,"type":20},"2025-07",{"name":42,"class":43},{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":336,"enrollmentInfo":337,"targetDuration":4,"studyType":21,"phases":339,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":44},"100355336","phase-4-bupivacaineepinephrine-dexamethasone-vs-liposomal-bupivacaine-100355336","NCT03906617","Bupivacaine\u002FEpinephrine +Dexamethasone vs. Liposomal Bupivacaine","Title of Project: Liposomal Bupivacaine (Exparel) Versus Bupivacaine And Dexamethasone Intercostal Nerve Blocks For Robotic Thoracic Surgery: A Prospective Randomized Single-Blinded Clinical Trial","Inclusion Criteria:\n\n* undergoing robotic wedge resection or lobectomy for lung mass(es)\n\nExclusion Criteria:\n\n* emergency case\n* history of opiate abuse\n* chronic pain syndrome\n* intravenous drug use\n* chronic use of oral steroids\n* pregnancy\n* imprisonment\n* body weight lower than 70 kg\n* liver failure\n* uninsured patients\n* non-verbal patients or patients who are unable to rate their pain on a visual analogue pain scale\n* history of allergic reaction to any of the drugs used in the study: bupivacaine, liposomal bupivacaine, dexamethasone","90 Years",{"count":338,"type":20},34,[126],"This study will assess analgesia after robotic lung surgery. Subjects will be randomized to receive wound infiltration and intercostal nerve block with either liposomal bupivacaine or bupivacaine\u002Fepinephrine + dexamethasone. Liposomal bupivacaine is a newer local anesthetic product and has not been compared to a combination of bupivacaine\u002Fepinephrine + dexamethasone in the context of pain control after robotic lung surgery.",[342],"Robotic Lung Surgery","2021-11-11",{"date":345,"type":36},"2021-11-12",{"date":347,"type":36},"2019-04-10",{"date":349,"type":20},"2022-06-10",{"name":42,"class":43},""]